Facebook-f Twitter Linkedin Youtube
SUBSCRIBE
Facebook-f Twitter Linkedin Youtube
SUBSCRIBE

Transplant CE Activities

RMEI DECISION SUPPORT AIDS

View Details

Refractory & Resistant Cytomegalovirus (CMV) in Solid Organ Transplant: Decision Support Aid

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
  • Transplant
  • Decision Support Aid
DOWNLOAD

RMEI Presentations

LATEST TRANSPLANT ARTICLES

RSS Latest Transplant Articles
  • Kidney Transplantation after Clearing Anti-HLA Antibodies with CD19 CAR T Cells June 4, 2026
    This letter reports the clinical course of a broadly HLA-sensitized patient in whom anti-CD19 CAR T-cell therapy enabled successful kidney transplantation.
    Jens Schrezenmeier, Hector Rincon-Arevalo, Nils Lachmann, Diana Stauch, Brigitta Globke, Robert Öllinger, Lukas J. Lehner, Stella Lesch, Gerhard Krönke, David Simon, Dominic Borie, Mira Choi, Frederik Damm, Mareike Frick, Philip F. Halloran, Klemens Budde, Brian J.P. Huntly, Lars Bullinger, Kai-Uwe Eckardt, Thomas Dörner, Olaf Penack, Fabian Halleck, Eva Schrezenmeier
  • Targeting of Wnt–β-Catenin Pathway in Recurrent Ameloblastoma June 4, 2026
    In a patient with recurrent ameloblastoma, zolucatetide (formerly FOG-001) produced an ongoing partial response at 40 weeks, with resolution of solid tumor and cerebral edema. Elevated liver-enzyme levels were noted.
    Samuel J. Klempner, Moh’d Khushman, Kyriakos P. Papadopoulos, Meredith P. Pelster, Jordi A. Rodon, Rona Yaeger, Shivaani Kummar, Sunil Sharma, David Bajor, Dennis Hsu, Ranjodh S. Dhami, Bayan Alzumaili, Jeremy D. Kratz, Varun Monga, Alexander Philipovskiy, Jorge Ramos, Amber Wells, Marie H. Nguyen, Jonathan B. Hurov, Michael Cecchini
  • Brief Report: Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy June 4, 2026
    HLA sensitization poses major challenges to kidney transplantation. This report describes transplantation in two highly sensitized candidates after desensitization with dual CAR T-cell therapy.
    Vijay G. Bhoj, Mary Kaminski, Huiwu Zhao, Kyle Jackson, Wei Wang, Chengyang Liu, Robert A. Montgomery, Nicole Ali, Massimo Mangiola, Thomas R. Spitzer, Kassem Safa, Vikram Pattanayak, Raeda Taj, Joy Chiu, Thanh-Mai Bui, Elizabeth M. Sonnenberg, James F. Markmann, Michael C. Milone, Carl H. June, Don L. Siegel, Joseph A. Fraietta, Vanessa Gonzalez, Michela Locci, Matthew Palmer, Dimitri Monos, Wei-Ting Hwang, Tina Sledge, Nancy D. Bridges, Julia S. Goldstein, Jonah Odim, Stuart C. Sweet, Behdad D. Besharatian, Sabiha M. Hussain, Nicholas K. Brown, Malek Kamoun, Alfred L. Garfall, Ali Naji

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
  • Allergy & Immunology
  • 2021
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.
  • Gastroenterology
  • 2021

Previously Published CE Activities